Phase 3 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Male patients who have prostate cancer that has not spread beyond the prostate (stages cT1c–T2c) and are planning to have a nerve-sparing robotic prostate removal surgery
- People whose prostate-specific antigen (PSA) blood test result was below 15 ng/ml in the last 12 months, and whose prostate cancer has been confirmed by biopsy, and for whom additional treatments like radiation or hormone therapy are not expected to be needed after surgery
- People aged between 45 and 75 years old
- People who scored 17 or higher on a standard erectile function questionnaire (called the IIEF-5) at the time of screening
- People who have had regular sexual activity for at least 6 months, including in the 12 weeks before their prostate biopsy or surgery
- People who are willing to avoid any erectile dysfunction treatments until at least 3 months after surgery
- People who are willing to take part and are able to give their informed consent to participate
Who may not be able to join:
- People for whom additional treatment (such as radiation) is planned after surgery because the cancer was found to have spread further than expected, or because lymph nodes or surgical margins were affected
- People who received treatment for their prostate cancer before surgery
- People with a history of prostate cancer that has come back
- People with a history of seizures, multiple sclerosis, stroke, or any other diagnosed neurological (nervous system) condition
- People whose prostate cancer has spread beyond the prostate or to other parts of the body (stage T3 or higher)
- People with a known allergy or sensitivity to a medication called 4-aminopyridine (4AP)
- People who have had penile surgery other than circumcision or a specific type of minor urethral procedure
- People with reduced kidney function, based on a kidney filtering rate test result below 60 mL/min
- People currently taking any medication from the aminopyridine drug family for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rashid Sayyid, MD, University of Arizona
Phone: 520-626-6456
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Michigan Incontinence Sympton Index (M-ISI) (change over time); International Index of Erectile Function (IIEF) (change over time); Placebo vs. Active Drug Questionnaire
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.